Company Of The Day: Walmart
What?
Retail behemoth Walmart (NYSE:WMT) plans to launch its own brand of insulin called ReliOn, which will be available at Walmart pharmacies this week and at Sam’s Club pharmacies by mid-July.
Why?
- Where Is Walmart Stock Headed Post Stock Split?
- Up 7% Already This Year , Where Is Walmart Stock Headed Post Q4 Results?
- Up 18% This Year, Will Walmart Stock Continue To Grow Past Q3?
- Can Walmart’s Stock Trade Lower Post Q2?
- Walmart Stock Likely To See Little Movement Post Q1
- Walmart Stock To Trade Lower Post Q3 Results?
Prices for insulin have been surging, proving a financial burden on people with diabetes. Walmart claims that its insulin could be between 58% to 75% cheaper versus branded products.
So What?
Walmart is looking to play a bigger role in the affordable healthcare space, with plans to open over 4000 clinics by 2029. Selling its own branded insulin could be a good starting point, given that the drug is relatively expensive and widely used.
See Our Complete Analysis For Walmart
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams